Hookipa Pharma - HOOK Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings or view top-rated stocks.

6 analysts have issued 12-month target prices for Hookipa Pharma's shares. Their HOOK share price forecasts range from $3.00 to $16.00. On average, they predict the company's stock price to reach $8.83 in the next twelve months. This suggests a possible upside of 425.8% from the stock's current price.
View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts.

Hookipa Pharma's stock was trading at $2.33 at the beginning of the year. Since then, HOOK shares have decreased by 27.9% and is now trading at $1.68.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our HOOK earnings forecast.

Hookipa Pharma Inc (NASDAQ:HOOK) posted its earnings results on Monday, May, 16th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.28. The business earned $1.45 million during the quarter, compared to the consensus estimate of $21.05 million. Hookipa Pharma had a negative net margin of 632.09% and a negative trailing twelve-month return on equity of 65.62%. During the same quarter last year, the firm earned ($0.53) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX).

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Hookipa Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.17%), Northern Trust Corp (0.11%), Group One Trading L.P. (0.00%), Virtu Financial LLC (0.05%), Concourse Financial Group Securities Inc. (0.00%) and Sculptor Capital LP (0.00%). Insiders that own company stock include Anders Lilja, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends.

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HOOK stock can currently be purchased for approximately $1.68.

Hookipa Pharma (NASDAQ:HOOK) has a market capitalization of $91.88 million and generates $18.45 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The official website for the company is www.hookipapharma.com. The company can be reached via phone at 431-890-6360, via email at ir@hookipapharma.com, or via fax at 43-1890-636-0399.